ASCO GI 2023 | INTEGRATE IIa: regorafenib in refractory advanced gastro-esophageal cancer

Regorafenib has demonstrated positive signals in patients with advanced gastroesophageal cancer. Nick Pavlakis, PhD, MBBS, FRACP, Royal North Shore Hospital, Sydney, Australia, discusses the results of INTEGRATE IIa (NCT02773524), a randomized, Phase III, double-blind trial of regorafenib versus placebo in refractory advanced gastroesophageal cancer. Regorafenib significantly improved overall survival in patients compared to placebo. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.